Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers

Khetam Hussein; Halima Dabaja-Younis; Moran Szwarcwort-Cohen; Ronit Almog; Ronit Leiba; Avi Weissman; Michal Mekel; Gila Hyams; Nethanel A. Horowitz; Vardit Gepstein; Hagar Cohen Saban; Jalal Tarabeia; Michael Halberthal; Yael Shachor-Meyouhas

doi:10.3390/vaccines10101741

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers

Khetam Hussein, Halima Dabaja-Younis, Moran Szwarcwort-Cohen, Ronit Almog, Ronit Leiba, Avi Weissman, Michal Mekel, Gila Hyams, Nethanel A. Horowitz, Vardit Gepstein, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Yael Shachor-Meyouhas

Research output: Contribution to journal › Article › peer-review

Abstract

This study assessed humoral response to the third BNT162b2 dose among healthcare workers (HCW). This prospective cohort study of HCW tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) at 1, 3, 6, 9, and 12 months after receiving the second BNT162b2 vaccine dose (tests 1, 2, 3, 4, and 5, respectively). A third (booster) vaccination dose was introduced before test 4. Linear regression model was used to determine the humoral response following vaccine doses. For each serology test, changes in log-transformed antibody concentrations over time, adjusted for age, sex, underlying diseases, steroid treatment, and smoking were described using the general linear mix model. Serology tests were performed at 3, 6, 9, and 12 months after the second vaccine dose in 1113, 1058, 986, and 939 participants, respectively. The third dose was received by 964 participants before the 9-month tests, 797 of whom participated in the 9- and 12-month serology tests. A significant inverse correlation was noted between time from third dose and antibody concentrations (Spearman correlation −0.395; p < 0.001). Age (p < 0.0001; CI 95% −0.005–−0.004), heart disease (p < 0.0001; CI 95% −0.177–−0.052), immunodeficiency (p < 0.0001; CI 95% 0.251–−0.106), and smoking (p < 0.0001; CI 95% −0.122–−0.040) were significantly associated with decreased antibody concentrations. Female sex (p = 0.03; CI 95% 0.013–0.066) was associated with increased antibody concentrations. The third booster dose had a better effect on immunogenicity, with higher antibody concentrations among tested HCW. Heart disease, smoking, and other known risk factors were associated with decreased antibody concentrations.

Original language	English
Article number	1741
Journal	Vaccines
Volume	10
Issue number	10
DOIs	https://doi.org/10.3390/vaccines10101741
State	Published - Oct 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Keywords

BNT162b2 vaccine
SARS-CoV-2
antibody concentrations
booster
humoral response

ASJC Scopus subject areas

Immunology
Pharmacology
Drug Discovery
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines10101741

Cite this

Hussein, K., Dabaja-Younis, H., Szwarcwort-Cohen, M., Almog, R., Leiba, R., Weissman, A., Mekel, M., Hyams, G., Horowitz, N. A., Gepstein, V., Cohen Saban, H., Tarabeia, J., Halberthal, M., & Shachor-Meyouhas, Y. (2022). Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers. Vaccines, 10(10), Article 1741. https://doi.org/10.3390/vaccines10101741

@article{65fefbe2d4664c5390c29350cfddd1ad,

title = "Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers",

abstract = "This study assessed humoral response to the third BNT162b2 dose among healthcare workers (HCW). This prospective cohort study of HCW tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) at 1, 3, 6, 9, and 12 months after receiving the second BNT162b2 vaccine dose (tests 1, 2, 3, 4, and 5, respectively). A third (booster) vaccination dose was introduced before test 4. Linear regression model was used to determine the humoral response following vaccine doses. For each serology test, changes in log-transformed antibody concentrations over time, adjusted for age, sex, underlying diseases, steroid treatment, and smoking were described using the general linear mix model. Serology tests were performed at 3, 6, 9, and 12 months after the second vaccine dose in 1113, 1058, 986, and 939 participants, respectively. The third dose was received by 964 participants before the 9-month tests, 797 of whom participated in the 9- and 12-month serology tests. A significant inverse correlation was noted between time from third dose and antibody concentrations (Spearman correlation −0.395; p < 0.001). Age (p < 0.0001; CI 95% −0.005–−0.004), heart disease (p < 0.0001; CI 95% −0.177–−0.052), immunodeficiency (p < 0.0001; CI 95% 0.251–−0.106), and smoking (p < 0.0001; CI 95% −0.122–−0.040) were significantly associated with decreased antibody concentrations. Female sex (p = 0.03; CI 95% 0.013–0.066) was associated with increased antibody concentrations. The third booster dose had a better effect on immunogenicity, with higher antibody concentrations among tested HCW. Heart disease, smoking, and other known risk factors were associated with decreased antibody concentrations.",

keywords = "BNT162b2 vaccine, SARS-CoV-2, antibody concentrations, booster, humoral response",

author = "Khetam Hussein and Halima Dabaja-Younis and Moran Szwarcwort-Cohen and Ronit Almog and Ronit Leiba and Avi Weissman and Michal Mekel and Gila Hyams and Horowitz, {Nethanel A.} and Vardit Gepstein and {Cohen Saban}, Hagar and Jalal Tarabeia and Michael Halberthal and Yael Shachor-Meyouhas",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = oct,

doi = "10.3390/vaccines10101741",

language = "English",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "10",

}

Hussein, K, Dabaja-Younis, H, Szwarcwort-Cohen, M, Almog, R, Leiba, R, Weissman, A, Mekel, M, Hyams, G, Horowitz, NA, Gepstein, V, Cohen Saban, H, Tarabeia, J, Halberthal, M & Shachor-Meyouhas, Y 2022, 'Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers', Vaccines, vol. 10, no. 10, 1741. https://doi.org/10.3390/vaccines10101741

TY - JOUR

T1 - Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers

AU - Hussein, Khetam

AU - Dabaja-Younis, Halima

AU - Szwarcwort-Cohen, Moran

AU - Almog, Ronit

AU - Leiba, Ronit

AU - Weissman, Avi

AU - Mekel, Michal

AU - Hyams, Gila

AU - Horowitz, Nethanel A.

AU - Gepstein, Vardit

AU - Cohen Saban, Hagar

AU - Tarabeia, Jalal

AU - Halberthal, Michael

AU - Shachor-Meyouhas, Yael

PY - 2022/10

Y1 - 2022/10

N2 - This study assessed humoral response to the third BNT162b2 dose among healthcare workers (HCW). This prospective cohort study of HCW tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) at 1, 3, 6, 9, and 12 months after receiving the second BNT162b2 vaccine dose (tests 1, 2, 3, 4, and 5, respectively). A third (booster) vaccination dose was introduced before test 4. Linear regression model was used to determine the humoral response following vaccine doses. For each serology test, changes in log-transformed antibody concentrations over time, adjusted for age, sex, underlying diseases, steroid treatment, and smoking were described using the general linear mix model. Serology tests were performed at 3, 6, 9, and 12 months after the second vaccine dose in 1113, 1058, 986, and 939 participants, respectively. The third dose was received by 964 participants before the 9-month tests, 797 of whom participated in the 9- and 12-month serology tests. A significant inverse correlation was noted between time from third dose and antibody concentrations (Spearman correlation −0.395; p < 0.001). Age (p < 0.0001; CI 95% −0.005–−0.004), heart disease (p < 0.0001; CI 95% −0.177–−0.052), immunodeficiency (p < 0.0001; CI 95% 0.251–−0.106), and smoking (p < 0.0001; CI 95% −0.122–−0.040) were significantly associated with decreased antibody concentrations. Female sex (p = 0.03; CI 95% 0.013–0.066) was associated with increased antibody concentrations. The third booster dose had a better effect on immunogenicity, with higher antibody concentrations among tested HCW. Heart disease, smoking, and other known risk factors were associated with decreased antibody concentrations.

AB - This study assessed humoral response to the third BNT162b2 dose among healthcare workers (HCW). This prospective cohort study of HCW tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) at 1, 3, 6, 9, and 12 months after receiving the second BNT162b2 vaccine dose (tests 1, 2, 3, 4, and 5, respectively). A third (booster) vaccination dose was introduced before test 4. Linear regression model was used to determine the humoral response following vaccine doses. For each serology test, changes in log-transformed antibody concentrations over time, adjusted for age, sex, underlying diseases, steroid treatment, and smoking were described using the general linear mix model. Serology tests were performed at 3, 6, 9, and 12 months after the second vaccine dose in 1113, 1058, 986, and 939 participants, respectively. The third dose was received by 964 participants before the 9-month tests, 797 of whom participated in the 9- and 12-month serology tests. A significant inverse correlation was noted between time from third dose and antibody concentrations (Spearman correlation −0.395; p < 0.001). Age (p < 0.0001; CI 95% −0.005–−0.004), heart disease (p < 0.0001; CI 95% −0.177–−0.052), immunodeficiency (p < 0.0001; CI 95% 0.251–−0.106), and smoking (p < 0.0001; CI 95% −0.122–−0.040) were significantly associated with decreased antibody concentrations. Female sex (p = 0.03; CI 95% 0.013–0.066) was associated with increased antibody concentrations. The third booster dose had a better effect on immunogenicity, with higher antibody concentrations among tested HCW. Heart disease, smoking, and other known risk factors were associated with decreased antibody concentrations.

KW - BNT162b2 vaccine

KW - SARS-CoV-2

KW - antibody concentrations

KW - booster

KW - humoral response

UR - http://www.scopus.com/inward/record.url?scp=85140742851&partnerID=8YFLogxK

U2 - 10.3390/vaccines10101741

DO - 10.3390/vaccines10101741

M3 - Article

C2 - 36298606

AN - SCOPUS:85140742851

SN - 2076-393X

VL - 10

JO - Vaccines

JF - Vaccines

IS - 10

M1 - 1741

ER -

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this